Key highlights
- Naoya Iwata will become OrganOx CEO & President effective June 1, 2026.
- Iwata has over 20 years at Terumo Corporation, including sales, strategy, business development and serving as Chief of Staff to CEO Hikaru Samejima.
- OrganOx's metra normothermic machine perfusion platform is approved in the U.S., Europe and Australia and licensed in Canada.
- The metra has been used in over 10,000 liver transplants; OrganOx was spun out of the University of Oxford in 2008.
Leadership change
Naoya Iwata will assume the role of Chief Executive Officer & President at OrganOx effective June 1, 2026.
Experience
Iwata has more than two decades of international experience at Terumo Corporation across sales, marketing, strategic planning and business development, and most recently served as Chief of Staff to Terumo CEO Hikaru Samejima, supporting group-level strategic initiatives.
Mandate and transition
He will lead OrganOx's continued commercial growth and development of its normothermic machine perfusion platform technologies; Craig Marshall and Rupa Basu will continue supporting the company in advisory roles following their operational tenures.
